Mutant Gene Identified as Villain in Hardening of the Arteries
A genetic mutation expands lesions in the aorta and promotes coronary atherosclerosis, more commonly known as hardening of the arteries, according to a study by Yale School of Medicine in Cell Metabolism.
The researchers found that mice engineered without the Akt1 gene and fed a high cholesterol diet had many more signs of aortic atherosclerosis compared to their littermates. And, surprisingly, their coronary lesions were similar to humans, say the scientists.
“About 20 percent of the mice died spontaneously, perhaps due to an acute heart attack,” said William Sessa, senior author of the study, professor of pharmacology, and director of Yale’s vascular biology and therapeutics program.
Atherosclerosis is a chronic inflammatory response in arterial walls, in large part due to deposits of lipoproteins—which are plasma proteins that carry cholesterol and triglycerides. The “hardening” or “furring” of the arteries is caused by plaque formation.
In the vascular wall, Akt plays an important role in regulating the development of endothelial cells, which line the entire circulatory system, from the heart to the smallest capillary. Endothelial cells play an important role in regulating blood pressure, in blood clotting, in plaque formation in the arteries, and in formation of new blood vessels.
“The major finding of this study is that an absence of Akt1 aggravates atherosclerotic lesions, promotes coronary atherosclerosis, and may be a model of acute coronary syndromes,” Sessa said. “Specific activation of Akt1 may provide a therapeutic approach to decrease formation of lesions in the arterial wall and promote plaque stabilization to prevent an acute heart attack.”
One concern, he said, is that specific drugs are being developed to inhibit Akt in cancer patients to reduce progression of tumors, and that these drugs may also promote hardening of the arteries.
Co-authors include Carlos Fernandez-Hernando, Eric Ackah, Jun Yu, Yajaira Suarez, Takahisa Murata, Yasuko Iwakiri, Jay Prendergast, and Robert Miao, of Yale, and Morris Birnbaum of the Howard Hughes Medical Institute and the University of Pennsylvania School of Medicine.
Cell Metabolism 6: 446-457 (December 2007)
The work above was funded, fully or in part, by the Yale Clinical and Translational Science Award (CTSA) grant from the National Center for Research Resources at the National Institutes of Health.